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Abstract 
Background: Pediatric patients with liver disease require noninvasive monitoring to evaluate the risk of fibrosis 
progression. This study aimed to identify the significant factors affecting liver stiffness values using two‑dimensional 
shear‑wave elastography (2D‑SWE), and determine whether liver stiffness can predict the fibrosis stage of various 
childhood liver diseases.
Methods: This study included 30 children (22 boys and 8 girls; mean age, 5.1 ± 6.1 years; range, 7 days–17.9 years) 
who had undergone biochemical evaluation, 2D‑SWE examination, histopathologic analysis of fibrosis grade (F0 to 
F3), assessment of necroinflammatory activity, and steatosis grading between August 2016 and March 2020. The liver 
stiffness from 2D‑SWE was compared between fibrosis stages using Kruskal–Wallis analysis. Factors that significantly 
affected liver stiffness were evaluated using univariate and multivariate linear regression analyses. The diagnostic per‑
formance was determined from the area under the receiver operating curve (AUC) values of 2D‑SWE liver stiffness.
Results: Liver stiffness at the F0‑1, F2, and F3 stages were 7.9, 13.2, and 21.7 kPa, respectively (P < 0.001). Both fibrosis 
stage and necroinflammatory grade were significantly associated with liver stiffness (P < 0.001 and P = 0.021, respec‑
tively). However, in patients with alanine aminotransferase (ALT) levels below 200 IU/L, the only factor affecting liver 
stiffness was fibrosis stage (P = 0.030). The liver stiffness value could distinguish significant fibrosis (≥ F2) with an AUC 
of 0.950 (cutoff value, 11.3 kPa) and severe fibrosis (F3 stage) with an AUC of 0.924 (cutoff value, 18.1 kPa). The 2D‑SWE 
values for differentiating significant fibrosis were 10.5 kPa (≥ F2) and 18.1 kPa (F3) in patients with ALT levels below 
200 IU/L.
Conclusion: The liver stiffness values on 2D‑SWE can be affected by both fibrosis and necroinflammatory grade and 
can provide excellent diagnostic performance in evaluating the fibrosis stage in various pediatric liver diseases. How‑
ever, clinicians should be mindful of potential confounders, such as necroinflammatory activity or transaminase level, 
when performing 2D‑SWE measurements for liver fibrosis staging.
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Background
Pediatric liver diseases have a wide range of etiologies, 
including congenital, metabolic, toxic, and infectious 
diseases, as well as a fatty liver [1]. Prolonged, repeated 
hepatocellular injury can lead to liver fibrosis, especially 
in pediatric patients who may exhibit an unpredictable 
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progression [2]. Therefore, pediatric patients with liver 
disease require monitoring for the likelihood of liver 
fibrosis progression similar to adult patients.
Both liver function biochemical assessment and 
ultrasound (US) examination are used for liver fibrosis 
monitoring, but liver biopsy, which is performed only 
if necessary, is considered the gold standard despite its 
invasiveness and potential for sampling errors [1]. Vari-
ous noninvasive monitoring methods, such as serum 
biochemical markers and quantitative liver elastography 
assessments, are promising alternatives to liver biopsy. 
Previous studies have shown that various serum bio-
chemical indicators, such as aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), AST to platelet 
ratio index (APRI), AST and ALT ratio (AAR), and fibro-
sis index based on the 4 factor (FIB-4) score, could be 
candidate markers in adult chronic liver patients [3–5]. 
However, further evaluation of their clinical utility for 
liver fibrosis is needed in pediatric patients because of 
their different etiologies [6, 7].
Noninvasive US elastography, which measures liver 
stiffness mainly on the basis of fibrosis, could be another 
option for monitoring fibrosis, in pediatric liver diseases 
[8]. The two-dimensional shear-wave elastography (2D-
SWE) value (obtained in m/s, and then converted in 
Young’s module unit in kilopascals [kPa] by making some 
assumptions) offers advantages in quantitative assess-
ment, and several studies have reported the clinical utility 
of 2D-SWE to assess liver fibrosis in chronic liver disease 
[9–12]. However, only a few studies have used 2D-SWE 
to evaluate the clinical significance of 2D-SWE liver stiff-
ness in pediatric patients with liver diseases, even though 
many studies have evaluated the advantages of SWE in 
adult populations with non-alcoholic fatty liver disease 
(NAFLD), hepatitis, autoimmune hepatitis, or other liver 
diseases [12–16].
Therefore, this study evaluated the significant factors 
influencing liver stiffness values in 2D-SWE and deter-
mined whether liver stiffness can predict the fibrosis 
stage of various childhood liver diseases.
Methods
Following the Declaration of Helsinki, the study was 
approved as a retrospective human study by the Institu-
tional Review Board of Seoul National University Hos-
pital (No. 2005-211-1127). Informed consent from the 
patients, parents, or guardians was waived accordingly.
Patient population
Patients with suspected liver disease were referred for 
liver biopsies to assess their histopathological conditions 
between August 2016 and March 2020. We retrospec-
tively reviewed the picture archiving and communication 
system (Infinitt; Infinitt Healthcare, Korea) database. 
The patients in our study were included as follows: (1) 
patients aged < 18  years; (2) patients who had under-
gone both 2D-SWE examination and serological bio-
chemical marker evaluation before the liver biopsy; and 
(3) patients who had obtained histopathological results 
through a liver biopsy for various liver diseases.
Fourteen patients were excluded from this study for 
the following reasons: insufficient quality of SWE as 
explained in the 2D-SWE Liver Stiffness Examination 
section (n = 6), use of different probes such as the high-
frequency linear probes (n = 4), and the cases of differ-
ent US machines due to the retrospective study design 
(n = 4). The number of excluded patients was 14, with a 
mean age of 2.1 ± 4.1 years (range 5 days–12.1 years). The 
most common histopathologic diagnoses in the excluded 
patients were biliary atresia (BA) (n = 8), and the oth-
ers included hepatitis (n = 3), Alagille syndrome (n = 1), 
undiagnosed disease (n = 1), and transient myeloprolif-
erative disorder (n = 1) (Fig. 1).
Serum biochemical analysis was performed on all 
patients within 1  week before liver biopsy. Serum lev-
els of total bilirubin, alkaline phosphatase, AST, ALT, 
γ-glutamyl transpeptidase, direct bilirubin, and albumin 
were measured, as were prothrombin time and platelet 
counts. We calculated the APRI, AAR, and FIB-4 scores 
[3, 4, 17].
2D‑SWE liver stiffness examination
All included patients had available results of liver US 
examination, including 2D-SWE elastography, without 
any anesthesia at least 3 days before or on the day of liver 
biopsy. The 2D-SWE examinations were performed by 
two experienced pediatric radiologists who were ran-
domly assigned (S.L. and Y.H.C. with 6 and 13  years of 
pediatric US examination experience, respectively) using 
the Aixplorer machine (SuperSonic Imagine SA, France) 
with a convex probe (SC6–1). The 2D-SWE examinations 
were performed according to the US elastography guide-
line previously reported.8 Patients had maintained a fast-
ing state for a minimum of 2 h before US and 2D-SWE 
examinations and for a minimum of 4 h to evaluate gall-
bladder morphology if BA was suspected.
The patient was placed in a supine position to visual-
ize the liver’s right lobe, and we set a 2.0 × 2.0-cm color-
coded box at a distance of 1.0 cm away from the Glisson’s 
capsule, avoiding large blood vessels. A 10  mm circular 
region of interest (ROI) was carefully placed over an 
evenly color-coded area in the SWE box. We obtained 
the liver stiffness values, standard deviations, and sta-
bility index (SI) values in the ROIs. All measurements 
were performed using SI, and only ROIs with SI values 
of 90% or higher were considered for evaluation [18, 19]. 
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Information with SI calculation allowed the user to rule 
out low-quality signals before calculating the interquar-
tile range (IQR). In this study, liver stiffness measure-
ments were considered successful when ROIs with SI 
values of 90% or higher were obtained across the entire 
series of SWE images. Otherwise, the measurement was 
considered to have failed and of insufficient image qual-
ity. In addition, when the normalized value divided by 
the IQR/median value from a total of 10 measurements 
showed a variation of 30% or more, the liver stiffness 
measurement was regarded as insufficient quality of the 
dataset because of the high variable measurability of the 
stiffness value [18, 20]. Finally, we selected the median 
liver stiffness values among sufficiently qualified images 
and stable measured data for further analysis.
Histopathologic analysis
Within 3 days of the US examination including 2D-SWE, 
the patients underwent percutaneous liver parenchymal 
biopsy with an 18-gauge core biopsy device (TSK Ace-
cut; Japan) while maintaining mild to moderate seda-
tion using intravenous sedative drugs. We performed a 
biopsy at the right lobe of the previously measured loca-
tion for each patient, without any significant adverse 
events. According to our protocols, biopsy samples were 
obtained three times with a specimen length of 11 mm or 
two times with a specimen length of 22 mm.
Two pediatric pathologists (J.K., with 6 years of expe-
rience in liver histopathologic evaluation and G.H.K., 
over 20  years of experience in pediatric gastrointesti-
nal pathology), who were not aware of the US results 
for SWE values, reviewed the specimens by consensus. 
We retrospectively reviewed the pathologic reports and 
assessed the stages of liver fibrosis using the META-
VIR staging system. We staged fibrosis on a five-point 
ordinal scale from 0 to 4 as follows: F0, absent and F4, 
cirrhosis [13]. We evaluated the liver necroinflamma-
tory activity grade from 0 to 3: A0, no activity and A3, 
severe activity [21]. We also graded the similar steato-
sis grade from 0 to 3: S0, no steatosis and S3, above the 
two-third fatty accumulation in the hepatocytes [22].
Statistical analyses
Descriptive demographic data were expressed as 
mean ± standard deviation. The median liver stiff-
ness values were compared among the fibrosis stages 
using the Kruskal–Wallis analysis. The significant fac-
tors affecting liver stiffness were assessed using lin-
ear regression methods by univariate and multivariate 
analyses.
The areas under the receiver operating characteris-
tic curves (AUCs) were analyzed to assess the diagnos-
tic performance of 2D-SWE liver stiffness values for the 
presence of significant fibrosis (≥ F2) and advanced fibro-
sis (F3). We also calculated the optimal cutoff values at 
the highest Youden index and identified the sensitivity, 
specificity, positive predictive values, and negative pre-
dictive values.
Statistical analyses were performed using SPSS Statis-
tics (version 21.0; IBM Corp., USA).
Fig. 1 Flowchart illustrating the selection of the study population. We retrospectively reviewed the picture archiving and communication system 
database for the period between August 2016 and March 2020. Of the 44 potential candidates who underwent two‑dimensional shear‑wave 
elastography (SWE) prior to liver biopsy, 14 were excluded for the following reasons: insufficient quality of SWE (n = 6), use of different probes 
(n = 4), and use of different US machines (n = 4)
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Results
Clinical characteristics
A total of 30 patients were included in our study, and the 
average patient’s age was 5.1 ± 6.1  years (range 7  days–
17.9  years). There were 22 male patients (73.3%) in our 
study, and none of the patients had ascites.
Table  1 summarizes the etiology of liver disease and 
the results of the serological index. The histological 
diagnoses were as follows: hepatitis (n = 6), BA (n = 6), 
NAFLD (n = 5), and others (n = 13). The AST and ALT 
values showed a wide range in our study, which were 
384.2 ± 577.6 and 440.3 ± 655.9  IU/L. The serologic 
indices such as APRI, AAR, and FIB-4 were 5.0 ± 8.4, 
1.3 ± 1.2, and 0.4 ± 0.8, respectively.
The fibrosis grades, necroinflammatory activity, and 
steatosis grades are summarized in Table 1. In all analy-
ses, we considered the F0 and F1 stages to be identical. 
Only two patients showed no signs of fibrosis (F0) on 
histopathological analysis. One of these patients had 
hemosiderosis, and the other had a very rare metabolic 
liver disease, namely, carnitine palmitoyltransferase I 
deficiency. Therefore, we included these patients with 
F0 stage fibrosis in the F1 stage fibrosis group for sta-
tistical analysis, and the total number of patients in this 
combined F0-1 stage fibrosis group was 13. Subsequently, 
patients in fibrosis stages were divided into two sub-
groups: no or mild hepatic fibrosis (F0 and F1; n = 13) 
and significant hepatic fibrosis (F2 and F3; n = 17). Sig-
nificant necroinflammatory activity (A2 and A3; n = 12) 
and steatosis grade (S2 and S3; n = 4) were also found as 
histopathologic abnormalities (Table 1).
A total of 16 patients with ALT levels below 200 were 
included in the subgroup analysis to minimize the con-
founding effect due to the high transaminase levels 
(Additional file  1: Table  S1). The histological diagnoses 
were as follows: BA (n = 5), NAFLD (n = 4), hepatitis 
(n = 2), and others (n = 5). The AST and ALT values in 
the subgroup were 139.4 ± 137.1 and 97.6 ± 56.5 (IU/L). 
The serologic indices such as APRI, AAR, and FIB-4 were 
1.8 ± 2.8, 1.9 ± 1.5, and 0.5 ± 1.0, respectively. The degree 
of fibrosis was equally distributed as follows: F0 and F1 
(n = 8), and F2 and F3 (n = 8). Significant necroinflam-
matory activity (A2 and A3; n = 6) and steatosis grade (S2 
and S3; n = 3) were also observed in the subgroup.
Significant affecting factors to liver stiffness values
For 2D-SWE liver stiffness measurements, Table 2 sum-
marizes the median liver stiffness values according to 
Table 1 Clinical characteristics
† Progressive familial intrahepatic cholestasis (n = 3), glycogen storage disease (n = 2), hemosiderosis (n = 2), hemophagocytic lymphohistiocytosis (n = 2), 
autoimmune hepatitis (n = 2), congenital hepatic fibrosis (n = 1), and carnitine palmitoyltransferase I deficiency (n = 1). SD, standard deviation; AST, aspartate 
aminotransferase; IU, international units; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; FIB-4, fibrosis-4 score
Parameters Patients (n = 30)
Age (years, mean ± SD) [range] 3.6 ± 5.5 [7 days to 17.9 years]
Sex (n, male:female) 22:8
Etiology of liver disease (%)
 Hepatitis 6 (20.0)
 Biliary atresia 6 (20.0)
 Non‑alcoholic fatty liver disease 5 (16.7)
  Others† 13 (43.3)
Serologic Index
 AST (mean ± SD) (IU/L) [range] 384.2 ± 577.6 [32–2946]
 ALT (mean ± SD) (IU/L) [range] 440.3 ± 655.9 [12–3121]
 APRI (AST to platelet ratio index) (mean ± SD) [range] 5.0 ± 8.4 [0.3–42.1]
 AAR (AST to ALT ratio) (mean ± SD) [range] 1.3 ± 1.2 [0.2–5.0]
 FIB‑4 (fibrosis‑4 score) (mean ± SD) [range] 0.4 ± 0.8 [0.0–3.9]
Grade of fibrosis (%)
 F0‑1 (none or mild) 13 (43.3)
 F2‑3 (moderate or severe) 17 (56.7)
Necroinflammatory activity (%)
 A0‑1 (none or minimal) 18 (60.0)
 A2‑3 (mild or moderate) 12 (40.0)
Degree of steatosis (%)
 S0‑1 (none or mild < 33%) 26 (86.7)
 S2‑3 (moderate or severe, ≥ 33%) 4 (13.3)
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the fibrosis stage. There was a significant difference in 
liver stiffness values among the F0-1, F2, and F3 stages 
(P < 0.001). Table  3 shows the histologic, demographic, 
and serologic factors influencing 2D-SWE liver stiffness 
values. In the univariate analysis, fibrosis grade (odds 
ratio [OR] 4.064; 95% confidence interval [CI] 2.010–
6.117; P < 0.001) and necroinflammatory grade (OR 
2.189; 95% CI 0.099–4.280; P = 0.041) were associated 
with 2D-SWE liver stiffness values. In the multivariate 
linear regression analysis, fibrosis grade (OR 4.356, 95% 
CI 2.618–6.095; P < 0.001) and necroinflammatory grade 
(OR 2.207, 95% CI 0.365–4.050; P = 0.021) were signifi-
cantly associated with liver stiffness.
In the subgroup analysis, the factors affecting liver 
stiffness values were fibrosis stage (OR 5.189; 95% CI 
2.872–7.506; P < 0.001), necroinflammatory activity (OR 
4.594; 95% CI 1.458–7.730; P = 0.007), and AAR (OR 
2.078; 95% CI 0.472–3.683; P = 0.015) in the univariate 
linear regression analysis. Multivariate linear regression 
analysis showed that only fibrosis stage was significantly 
associated with the liver stiffness value (OR 3.149; 95% CI 
0.359–5.940; P = 0.030) (Additional file 1: Table S2).
Diagnostic performance of liver stiffness predicting fibrosis
The 2D-SWE liver stiffness values above 11.3 kPa showed 
94.1% sensitivity and 84.6% specificity in distinguish-
ing significant fibrosis (≥ F2) from no or mild fibrosis 
(AUC = 0.950; 95% CI 0.803–0.996; P < 0.001). At the 
advanced fibrosis stage F3, a liver stiffness value greater 
than 18.1 kPa showed 83.3% sensitivity and 100.0% speci-
ficity for differentiating fibrosis stages (AUC = 0.924; 
95% CI 0.766–0.989; P < 0.001) (Table 4). In the subgroup 
analysis, the 2D-SWE values for differentiating significant 
fibrosis were 10.5 kPa (≥ F2) and 18.1 kPa (F3) in patients 
with ALT below 200 (Additional file 1: Table S3).
Representative 2D-SWE and histopathologic speci-
mens of the F1 case are shown in Fig. 2a, b. Each 2D-SWE 
and histopathologic sample of F2 and F3 are shown in 
Figs. 3a, b and 4a, b, respectively.
Table 2 Median liver stiffness values in fibrosis stages
IQR is presented in parentheses. IQR, interquartile range. *P value was determined using Kruskal–Wallis analysis
Variable Fibrosis stages P value*
F0‑1 (n = 13) F2 (n = 11) F3 (n = 6)
Liver stiffness, kPa (IQR) 8.2 (7.3–10.9) 13.2 (12.6–15.8) 21.7 (17.4–23.7) < 0.001
Table 3 Factors affecting liver stiffness value determined by 2D‑SWE
2D-SWE, two-dimensional shear-wave elastography; CI, confidence interval; APRI, AST to platelet ratio index; AAR, AST to ALT ratio; FIB-4, fibrosis-4 score
Characteristics Univariate Multivariate
Coefficient 95% CI P value Coefficient 95% CI P value
Fibrosis Stage 4.064 2.010 to 6.117 < 0.001 4.356 2.618 to 6.095 < 0.001
Necroinflammatory activity 2.189 0.099 to 4.280 0.041 2.207 0.365 to 4.050 0.021
Steatosis grade 1.316 − 1.496 to 4.129 0.341 –
Age (years) ‑0.209 − 0.600 to 0.182 0.280 –
Sex ‑0.740 − 3.732 to 2.252 0.612 –
APRI ‑0.043 − 0.207 to 0.121 0.593 –
AAR 0.235 − 0.990 to 1.460 0.694 –
FIB‑4 0.959 − 1.268 to 3.187 0.381 –
Table 4 Diagnostic performance of 2D‑SWE for liver fibrosis
2D-SWE = two-dimensional shear-wave elastography. Diagnostic accuracy of each variable in association with fibrosis stage. The performance of the selected best 
cutoff values was indicated. AUC = the area under the receiver operating curve. PPV, positive predictive value; NPV, Negative predictive value; *Determined using 
receiver operating characteristic curve analysis
Stage Cutoff AUC (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%) P value*
F ≥ 2 > 11.3 0.950 (0.803–0.996) 94.1 84.6 84.2 90.9 < 0.001
F ≥ 3 > 18.1 0.924 (0.766–0.989) 83.3 100.0 100.0 96.0 < 0.001
Page 6 of 10Lee et al. BMC Med Imaging           (2021) 21:68 
Fig. 2 Glycogen storage disease of the liver in a 42‑month‑old boy. The serum biochemical marker levels were as follows: AST to platelet ratio 
index (APRI), 1.5; AST to alanine aminotransferase ratio (AAR), 0.9; and fibrosis‑4 (FIB‑4) score, 0.1. a Two‑dimensional shear‑wave elastography 
(2D‑SWE) showing diffuse hyperechoic parenchyma with 9.1 kPa liver stiffness value. b Histopathologic specimen showing diffuse enlargement of 
hepatocytes with clear cytoplasm and enlargement of the fibrotic portal tract with METAVIR score, F1
Fig. 3 Hemophagocytic lymphohistiocytosis combined with the hepatitis in a 2.2‑year‑old boy. The serum biochemical marker levels were as 
follows: AST to platelet ratio index (APRI), 14.5; AST to alanine aminotransferase ratio (AAR), 0.8; and fibrosis‑4 (FIB‑4) score, 0.4. a Two‑dimensional 
shear‑wave elastography (2D‑SWE) showing diffuse hyperechoic parenchyma with 14.7 kPa liver stiffness value. b Histopathologic specimen 
showing moderate lobular necroinflammatory activity and few portal fibrosis with METAVIR score, F2
Fig. 4 Non‑alcoholic fatty liver disease in a 13.9‑year‑old boy. The serum biochemical marker levels were as follows: AST to platelet ratio index 
(APRI), 1.3; AST to alanine aminotransferase ratio (AAR), 0.4; and fibrosis‑4 (FIB‑4) score, 0.4. a Two‑dimensional shear‑wave elastography (2D‑SWE) 
showing diffuse hyperechoic parenchyma with 21.2 kPa liver stiffness value. b Histopathologic specimen showing mild necroinflammatory activity, 
severe macrovesicular steatosis, and significant septal fibrosis with architectural distortion with METAVIR score, F3
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Discussion
Our study demonstrated that liver stiffness measure-
ments performed using 2D-SWE showed a significant 
association with liver fibrosis. Liver stiffness values 
may also be affected by necroinflammatory activity and 
transaminase levels. Therefore, a careful interpretation of 
liver stiffness is needed when fibrosis monitoring using 
2D-SWE in pediatric patients with various liver diseases 
is carried out.
Liver fibrosis involves the progressive deposition of col-
lagen material in the liver, which is a recovery response 
after chronic liver injury from various causes [23]. Non-
invasive monitoring of mild to moderate liver fibrosis is 
important because cirrhosis, the end result of fibrosis, 
is irreversible. Previous studies have reported the per-
formance of noninvasive diagnostic methods of liver 
fibrosis staging in adult patients [24–26]. A previous 
systematic review on 2D-SWE in liver fibrosis reported 
that the median cutoff value for presenting signifi-
cant liver fibrosis (≥ F2) was 8.0 kPa (range 7.1–10.5) in 
adult patients [25]. Although liver elastography has been 
widely reported to have excellent diagnostic performance 
in adult patients, only a few studies have applied it in 
pediatric patients because of the difficulty in controlling 
and coordinating breathing in these patients despite the 
advantage offered by US evaluation. Recently, Kim et al. 
[15] had reported that liver stiffness value might be an 
excellent diagnostic value for evaluating liver fibrosis in 
children and adolescents in a meta-analysis of five stud-
ies, with a cutoff value of 9.4  kPa, a similar value as in 
adult patients.
Our study showed similar or slightly higher cutoff 
values for each fibrosis stage than a previous study on 
pediatric patients. However, our cutoff values should 
be compared to those of previously reported pediatric 
studies on a similar disease etiology [10]. Dhyani et  al. 
reported that the cutoff value for the F2 stage would be 
8.8 kPa in children and adolescents with diverse liver dis-
eases [27]. Tutar et al. [28] and Franchi-Abella et al. [16] 
also reported that the cutoff values would be 10.4 kPa and 
12.1  kPa in patients with NAFLD and early stage fibro-
sis, respectively. Therefore, in each study, the cutoff value 
may differ because of various causes and patient age 
groups. Our study could not demonstrate the cutoff value 
for any specific disease because of the diverse etiologies 
of pediatric liver diseases. Nevertheless, the advantage of 
this study was that it yielded meaningful results similar to 
existing data without sedation, even in neonates.
We also evaluated a variety of biochemical markers 
that could affect liver fibrosis. Previous studies on adult 
patients with viral hepatitis reported that the fibro-
sis stage and gamma-glutamyl transpeptidase levels 
could influence the liver stiffness value measured using 
2D-SWE [24, 26]. Previous studies also reported that 
the APRI might be a diagnostic value in predicting the 
fibrosis stage in pediatric liver diseases [6, 29]. However, 
there was a controversy in the APRI diagnostic accu-
racy as a predictive indicator of liver fibrosis in children 
[6, 30]. In adults, these scoring systems could provide 
good diagnostic performance in not only NAFLD but 
also viral hepatitis [31]. Yang et al. [32] reported that the 
APRI and FIB-4 scores might be significant markers for 
predicting fibrosis in children with NAFLD. However, 
Mansoor et  al. [6] reported that the APRI, AAR, and 
FIB-4 scores had poor diagnostic performance in iden-
tifying significant fibrosis in patients with NAFLD. Even 
recently developed fibrosis prediction systems, such as 
the improved liver fibrosis (ELF) scoring system, require 
unique serum markers, making their general use difficult 
[33].
Our study showed that serum biochemical markers 
such as the APRI, AAR, and FIB-4 scores provided a wide 
range because of the characteristics of various pediatric 
liver diseases. Therefore, these serologic markers did not 
affect liver stiffness values in the univariate linear regres-
sion analysis. However, when the ALT level was below 
200 IU/L, AAR showed a significant association with the 
liver stiffness value despite the insignificance in the mul-
tivariate analysis. Therefore, a careful interpretation of 
liver stiffness is needed in various pediatric liver diseases 
because it is a confounding factor.
Among all the parameters explored in our study, fibro-
sis stage was the most relevant factor affecting 2D-SWE 
liver stiffness value. This could be because SWE can 
be applied to liver tissues to reflect the severity of liver 
fibrosis, even in various pediatric liver diseases. Another 
histopathologic factor, necroinflammatory grade, was rel-
evant to liver stiffness values in pediatric liver diseases. 
All these histologic factors might be related to the stage 
of liver fibrosis. We have shown that both necroinflam-
matory and fibrotic stages based on histopathologic anal-
ysis can influence 2D-SWE liver stiffness values despite 
various liver diseases. However, only the fibrosis stage 
affected the liver stiffness values in the subgroup analy-
sis. Therefore, the 2D-SWE liver stiffness value is a non-
invasive marker suitable for clinical settings because of 
its correlation with the histologic fibrosis stage in various 
pediatric liver diseases.
Our study included patients with cholestatic liver dis-
ease in almost one-third of the study population. Accord-
ing to the EFSUMB guidelines, there was no evidence of 
the usefulness of 2D-SWE measurements in pediatric 
cholestatic liver disease patients due to the paucity of 
data.8 However, a recent expert opinion had suggested 
that the 2D-SWE value could be a valuable marker in 
cholestatic liver disease [34]. Another recent study 
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reported that 2D-SWE value could be a valuable tool for 
predicting the stage of liver fibrosis in BA [35]. Neverthe-
less, large-scale cohort data for other cholestatic liver dis-
eases have not yet been reported due to their infrequent 
incidence. As mentioned in previous reports, cholestatic 
conditions and tissue swelling or inflammation can lead 
to increased liver stiffness; therefore, careful interpreta-
tion is needed regarding the possibility of liver stiffness 
value overestimation [36]. Researchers using 2D-SWE 
measurements for liver fibrosis staging have to keep in 
mind the possible confounders such as necroinflamma-
tory activity or transaminase level, but the various pedi-
atric liver diseases could be evaluated through 2D-SWE 
measurements without regulating these confounders.
In terms of the influence of steatosis on liver stiffness 
measurements, there were no significant results on the 
effect of liver stiffness in our study. The 2D-SWE value 
for NAFLD in pediatric patients showed a higher liver 
stiffness value in a previous study. However, consistent 
results have not yet been reported for the effect of stea-
tosis on 2D-SWE measurements obtained by US imaging 
in pediatric patients [37]. In fact, only four patients with 
significant steatosis were included in our study which was 
too small a sample size to assess the effect of liver stiff-
ness. Therefore, a further large cohort study is needed to 
determine the effect of steatosis on liver stiffness.
Magnetic resonance elastography (MRE) might be an 
alternative diagnostic tool for the liver fibrosis stage. The 
diagnostic performance and reproducibility of MRE is 
generally higher than that of SWE examination [38–40]. 
However, compared to ultrasound-based elastography 
examination, MRE has a longer acquisition time, higher 
cost, and requires sedation, especially for uncooperative 
pediatric patients.
The present study had several limitations. We included 
only a small number of patients with a wide age range 
from neonates to adolescents who underwent 2D-SWE 
evaluation. A small number of patients in each fibro-
sis stage, with different etiologies and broad age ranges, 
could limit the results and clinical implications. How-
ever, to date, there is a paucity of published literature 
regarding the real-world clinical performance of SWE 
in the pediatric population. At present, SWE techniques 
employed in children are based mostly on the adult lit-
erature and expert opinion as opposed to scientific evi-
dence; thus, continued research is still needed in this 
direction [34]. We believe that liver stiffness on SWE 
increases most often in response to increasing histologic 
fibrosis, although a variety of other pathologic and his-
tologic changes may impact these measurements. How-
ever, there is a limitation in designing large-scale studies 
due to the small number of rare pediatric liver diseases. 
Efforts to accumulate data on these various diseases are 
required to evaluate the usefulness of the SWE tech-
nique. The clinical usefulness of 2D-SWE technology 
should be established for suspected patients with liver 
disease even in undiagnosed situations. Therefore, if liver 
stiffness obtained from 2D-SWE data on these various 
causes can be collected and estimated, this technique 
could be applied not only to NAFLD or hepatitis but also 
to fibrosis monitoring in various diffuse liver diseases. 
The advantage of our study is that even these various 
liver diseases showed statistically significant higher diag-
nostic accuracy of SWE values along the fibrosis stages. 
Nevertheless, further research is warranted on the clini-
cal application of 2D-SWE in influencing the prognosis 
of suspected patients with liver diseases. The liver stiff-
ness value on 2D-SWE could be overestimated accord-
ing to the diverse etiologies such as severe inflammation, 
obstructive cholestasis, or congestive liver condition, 
which leads to an overestimation of the fibrosis stage 
[34]. Therefore, the liver stiffness cutoff values obtained 
in the present study might overestimate the stage of liver 
fibrosis rather than other cohorts and need the careful 
application of liver stiffness cutoff values that could only 
be applied to this series of patients.
Conclusion
In conclusion, the liver stiffness values from 2D-SWE 
can be affected by both fibrosis and necroinflammatory 
grades and can be an excellent diagnostic tool for fibro-
sis stage evaluation, even in various liver disease types. 
However, 2D-SWE measurements for liver fibrosis stag-
ing have to keep in mind the possible confounders such 
as necroinflammatory activity or transaminase level 
accordingly.
Abbreviations
AAR : The aspartate aminotransferase to alanine aminotransferase ratio; ALT: 
Alanine aminotransferase; APRI: The aspartate aminotransferase to platelet 
ratio index; AST: Aspartate aminotransferase; AUC : Areas under the ROC curve; 
BA: Biliary atresia; FIB‑4: Fibrosis‑4 score; NAFLD: Non‑alcoholic fatty liver dis‑
ease; ROC: Receiver operating characteristic; SWE: Shear‑wave elastography; 
US: Ultrasound.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12880‑ 021‑ 00601‑8.
Additional file 1. Subgroup Analysis in Patients with Alanine Aminotrans‑
ferase (ALT) < 200 (IU/L).
Acknowledgements
This work was supported by Grant No. 04‑2020‑0760 from the SNUH Research 
Fund and by the National Research Foundation of Korea (NRF) grant funded 
by the Korea government (MSIT) (No. 2020R1C1C1008716).
Page 9 of 10Lee et al. BMC Med Imaging           (2021) 21:68  
Authors’ contributions
SL and YHC: study concept and design, data acquisition, data analysis and 
interpretation, and writing of manuscript. SBL, JK, GHK: data analysis and 
interpretation. YJC, JEC, WSK, JSK: data acquisition and revision of manuscript 
for important intellectual content. All authors read and approved the final 
manuscript.
Funding
This work was supported by grant no 04–2020‑0760 from the SNUH Research 
Fund and by the National Research Foundation of Korea (NRF) grant funded 
by the Korea government (MSIT) (No. 2020R1C1C1008716). The funder had no 
involvement or influence whatsoever in the study design at any stage, collec‑
tion of the data or its analysis and interpretation, writing and preparation of 
the manuscript, or its submission for publication.
Availability of data and materials
The datasets used or analyzed during the current study are available from the 
corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
Following the Declaration of Helsinki, the study was approved as a retrospec‑
tive human study by the Institutional Review Board of Seoul National Univer‑





The authors have no competing interest to declare.
Author details
1 Department of Radiology, Seoul National University Hospital, 101 Daehak‑ro, 
Jongno‑gu, Seoul 03080, Republic of Korea. 2 Department of Radiology, 
Seoul National University College of Medicine, 103 Daehak‑ro, Jongno‑gu, 
Seoul 03080, Republic of Korea. 3 Institute of Radiation Medicine, Seoul 
National University Medical Research Center, 103 Daehak‑ro, Jongno‑gu, 
Seoul 03080, Republic of Korea. 4 Department of Pediatrics, Seoul National 
University Hospital, 101 Daehak‑ro, Jongno‑gu, Seoul 03080, Republic 
of Korea. 5 Department of Pathology, Seoul National University Hospital, 101 
Daehak‑ro, Jongno‑gu, Seoul 03080, Republic of Korea. 
Received: 17 December 2020   Accepted: 1 April 2021
References
 1. Jagadisan B, Srivastava A, Yachha SK, Poddar U. Acute on chronic liver dis‑
ease in children from the developing world: recognition and prognosis. J 
Pediatr Gastroenterol Nutr. 2012;54:77–82.
 2. Goss JA, Shackleton CR, McDiarmid SV, et al. Long‑term results of 
pediatric liver transplantation: an analysis of 569 transplants. Ann Surg. 
1998;228:411–20.
 3. Vallet‑Pichard A, Mallet V, Nalpas B, et al. FIB‑4: an inexpensive and accu‑
rate marker of fibrosis in HCV infection. comparison with liver biopsy and 
FibroTest. Hepatology. 2007;46:32–6.
 4. Loaeza‑del‑Castillo A, Paz‑Pineda F, Oviedo‑Cardenas E, Sanchez‑Avila F, 
Vorackova FV. AST to platelet ratio index (APRI) for the noninvasive evalu‑
ation of liver fibrosis. Ann Hepatol. 2008;7:350–7.
 5. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotrans‑
ferase‑to‑platelet ratio index for the staging of hepatitis C‑related fibrosis: 
an updated meta‑analysis. Hepatology. 2011;53:726–36.
 6. Mansoor S, Yerian L, Kohli R, et al. The evaluation of hepatic fibrosis 
scores in children with nonalcoholic fatty liver disease. Digest Dis Sci. 
2015;60:1440–7.
 7. de Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measure‑
ment in children using FibroScan: feasibility study and comparison with 
fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. 
J Pediatr Gastroenterol Nutr. 2007;45:443–50.
 8. Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB guidelines and 
recommendations on the clinical use of liver ultrasound elastography, 
Update 2017 (Long Version) (vol 38, pg e16, 2017). Ultraschall Med. 
2017;38:E52–E52.
 9. Belei O, Sporea I, Gradinaru‑Tascau O, et al. Comparison of three ultra‑
sound based elastographic techniques in children and adolescents with 
chronic diffuse liver diseases. Med Ultrason. 2016;18:145–50.
 10. Garcovich M, Veraldi S, Di Stasio E, et al. Liver stiffness in pediatric patients 
with fatty liver disease: diagnostic accuracy and reproducibility of shear‑
wave elastography. Radiology. 2017;283:820–7.
 11. Behairy Bel S, Sira MM, Zalata KR, el Salama SE, Abd‑Allah MA. Transient 
elastography compared to liver biopsy and morphometry for predicting 
fibrosis in pediatric chronic liver disease: does etiology matter? World J 
Gastroenterol. 2016;22:4238–49.
 12. Farmakis SG, Buchanan PM, Guzman MA, Hardy AK, Jain AK, Teckman JH. 
Shear wave elastography correlates with liver fibrosis scores in pediatric 
patients with liver disease. Pediatr Radiol. 2019;49:1742–53.
 13. Dhyani M, Grajo JR, Bhan AK, Corey K, Chung R, Samir AE. Validation 
of shear wave elastography cutoff values on the supersonic aixplorer 
for practical clinical use in liver fibrosis staging. Ultrasound Med Biol. 
2017;43:1125–33.
 14. Galina P, Alexopoulou E, Zellos A, et al. Performance of two–dimensional 
ultrasound shear wave elastography: reference values of normal liver 
stiffness in children. Pediatr Radiol. 2019;49:91–8.
 15. Kim JR, Suh CH, Yoon HM, Lee JS, Cho YA, Jung AY. The diagnostic 
performance of shear‑wave elastography for liver fibrosis in children and 
adolescents: a systematic review and diagnostic meta‑analysis. Eur Radiol. 
2018;28:1175–86.
 16. Franchi‑Abella S, Corno L, Gonzales E, et al. Feasibility and diagnostic 
accuracy of supersonic shear‑wave elastography for the assessment of 
liver stiffness and liver fibrosis in children: a pilot study of 96 patients. 
Radiology. 2016;278:554–62.
 17. Iacobellis A, Marcellini M, Andriulli A, et al. Non invasive evaluation of liver 
fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J 
Gastroenterol. 2006;12:7821–5.
 18. Hong EK, Choi YH, Cheon JE, Kim WS, Kim IO, Kang SY. Accurate meas‑
urements of liver stiffness using shear wave elastography in children 
and young adults and the role of the stability index. Ultrasonography. 
2018;37:226–32.
 19. Sporea I, Gradinaru‑Tascau O, Bota S, et al. How many measurements are 
needed for liver stiffness assessment by 2D‑Shear Wave Elastography 
(2D‑SWE) and which value should be used: the mean or median? Med 
Ultrason. 2013;15:268–72.
 20. Yoon JH, Lee JM, Han JK, Choi BI. Shear wave elastography for liver stiff‑
ness measurement in clinical sonographic examinations: evaluation of 
intraobserver reproducibility, technical failure, and unreliable stiffness 
measurements. J Ultrasound Med. 2014;33:437–47.
 21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic 
hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 
1996;24:289–93.
 22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander‑Tetri BA, Bacon 
BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the 
histological lesions. Am J Gastroenterol. 1999;94:2467–74.
 23. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cel‑
lular response to tissue injury. J Biol Chem. 2000;275:2247–50.
 24. Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two‑dimensional 
shear‑wave elastography performance in the noninvasive evaluation of 
liver fibrosis in patients with chronic hepatitis B: comparison with serum 
fibrosis indexes. Radiology. 2017;283:873–82.
 25. Jiang T, Tian G, Zhao Q, et al. Diagnostic accuracy of 2D‑shear wave 
elastography for liver fibrosis severity: a meta‑analysis. PLoS ONE. 
2016;11:e0157219.
 26. Zeng J, Liu GJ, Huang ZP, et al. Diagnostic accuracy of two‑dimensional 
shear wave elastography for the non‑invasive staging of hepatic fibrosis 
in chronic hepatitis B: a cohort study with internal validation. Eur Radiol. 
2014;24:2572–81.
 27. Dhyani M, Gee MS, Misdraji J, Israel EJ, Shah U, Samir AE. Feasibility 
study for assessing liver fibrosis in paediatric and adolescent patients 
Page 10 of 10Lee et al. BMC Med Imaging           (2021) 21:68 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
using real‑time shear wave elastography. J Med Imaging Radiat Oncol. 
2015;59:687–94.
 28. Tutar O, Beser OF, Adaletli I, et al. Shear wave elastography in the 
evaluation of liver fibrosis in children. J Pediatr Gastroenterol Nutr. 
2014;58:750–5.
 29. Li YY, Chen Y, Zhao Y. The diagnostic value of the FIB‑4 index for staging 
hepatitis B‑related fibrosis: a meta‑analysis. PLoS ONE. 2014;9:e105728.
 30. Chen S, Liao B, Zhong Z, et al. Supersonic shearwave elastography in the 
assessment of liver fibrosis for postoperative patients with biliary atresia. 
Sci Rep. 2016;6:31057.
 31. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 
2011;26:802–9.
 32. Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive Parameters and 
hepatic fibrosis scores in children with nonalcoholic fatty liver disease. 
World J Gastroenterol. 2012;18:1525–30.
 33. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF Serum Markers in 
Predicting Fibrosis Stage in Pediatric Non‑Alcoholic Fatty Liver Disease. 
Gastroenterology. 2009;136:160–7.
 34. Ferraioli G, Barr RG, Dillman JR. Elastography for pediatric chronic liver 
disease: a review and expert opinion. J Ultrasound Med. 2020. https:// doi. 
org/ 10. 1002/ jum. 15482.
 35. Chen H, Zhou L, Liao B, et al. Two‑dimensional shear wave elastography 
predicts liver fibrosis in Jaundiced infants with suspected biliary atresia: a 
prospective study. Korean J Radiol. 2021;22:e8.
 36. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis 
increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 
2008;48(5):1718–23.
 37. Alhashmi GH, Gupta A, Trout AT, Dillman JR. Two‑dimensional ultrasound 
shear wave elastography for identifying and staging liver fibrosis in pedi‑
atric patients with known or suspected liver disease: a clinical effective‑
ness study. Pediatr Radiol. 2020;50(9):1255–62.
 38. Yoon H, Shin HJ, Kim MJ, Lee MJ. Quantitative imaging in pediatric hepa‑
tobiliary disease. Korean J Radiol. 2019;20:1342–57.
 39. Kennedy P, Wagner M, Castera L, et al. Quantitative elastography methods 
in liver disease: current evidence and future directions. Radiology. 
2018;286:738–63.
 40. Yoon JH, Lee JM, Joo I, et al. Hepatic fibrosis: prospective comparison of 
MR elastography and US shear‑wave elastography for evaluation. Radiol‑
ogy. 2014;273:772–82.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
